Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.
How can patients with psychiatric or any other illnesses be viewed as non-compliant with their medical regimes when there is a persistent failure to investigate how their race and genetics are affecting treatment
CONNECT WITH US ON SOCIAL MEDIA
Medika.Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice.